Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: GlobeNewswire
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performanceR&D expenses grew 11.8%, reflecting strategic shift of resources into developmentSG&A expenses grew 2.9%, less than sales growthBusiness EPS(1) of €1.78, down 17.6% reported and 7.4% at CERIFRS EPS of €0.91, down 43.1% reported R&D transformation advanced further Three regulatory approvals: new Dupixent indications in the US and Japan and Beyfortus in JapanPositive phase 3 results for rilzabrutinib in immune thrombocytopenia, a rare diseaseReaffirming increasing pipeline news flow over
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger [Yahoo! Finance]Yahoo! Finance
- Sanofi's New Cancer Drug Could Help Deliver a Big Payday [Yahoo! Finance]Yahoo! Finance
- Pfizer Agrees to Settle More than 10,000 Zantac Cancer Lawsuits [BNN Bloomberg (Canada)]BNN Bloomberg
- 3 Top French Dividend Stocks Offering Up To 6.5% Yield [Yahoo! Finance]Yahoo! Finance
- Neurological Disorder Drugs Market is expected to reach a revenue of USD 103.8 Bn by 2033, at 5.1% CAGR: Dimension Market Research [Yahoo! Finance]Yahoo! Finance
SNY
Analyst Actions
- 2/12/24 - TheStreet
SNY
Sec Filings
- 5/2/24 - Form 6-K
- 4/25/24 - Form 6-K
- 4/4/24 - Form F-3ASR
- SNY's page on the SEC website